Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
Industry | Market Weight | YTD Return | |
---|---|---|---|
All Industries | 100.00% | 7.19% | |
Drug Manufacturers - General | 35.21% | 16.88% | |
Healthcare Plans | 12.84% | -4.08% | |
Biotechnology | 12.15% | 6.13% | |
Medical Devices | 12.11% | 2.20% | |
Diagnostics & Research | 10.90% | 2.27% | |
Medical Instruments & Supplies | 6.68% | 8.21% | |
Medical Care Facilities | 2.93% | 15.93% | |
Drug Manufacturers - Specialty & Generic | 2.74% | -2.02% | |
Medical Distribution | 2.27% | 8.49% | |
Health Information Services | 2.02% | 6.32% | |
Pharmaceutical Retailers | 0.15% | -55.22% |
Note: Percentage % data on heatmap indicates Day Return
All Industries
--
<= -3
-2
-1
0
1
2
>= 3
Largest Companies in This Sector
View MoreName | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
---|---|---|---|---|---|---|---|
948.40 | 798.75 | 12.76% | Buy | ||||
511.53 | 575.92 | 7.04% | Buy | ||||
149.88 | 158.15 | 5.39% | Buy | ||||
127.76 | 131.40 | 4.84% | Buy | ||||
170.28 | 184.12 | 4.49% | Buy | ||||
548.09 | 624.92 | 3.13% | Buy | ||||
246.70 | 272.04 | 2.73% | Buy | ||||
104.22 | 124.80 | 2.71% | Buy | ||||
330.83 | 318.42 | 2.65% | Buy | ||||
28.92 | 29.02 | 2.45% | Hold |
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
---|---|---|---|---|
148.27 | 39.084B | 0.09% | ||
272.12 | 20.601B | 0.10% | ||
145.03 | 7.363B | 0.45% | ||
98.96 | 7.126B | 0.35% | ||
56.46 | 5.134B | 0.40% |
Mutual Fund Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
---|---|---|---|---|
227.21 | 47.799B | 0.30% | ||
95.81 | 47.799B | 0.30% | ||
136.02 | 20.601B | 0.10% | ||
98.72 | 14.902B | 0.80% | ||
98.41 | 14.902B | 0.80% |
Healthcare Research
View MoreDiscover the Latest Analyst and Technical Research for This Sector
Analyst Report: Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
RatingPrice TargetAnalyst Report: Bio-Techne Corporation
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
RatingPrice TargetAnalyst Report: DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 250,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
RatingPrice TargetAnalyst Report: AbbVie Inc
AbbVie, a research-based biopharmaceutical company, was spun off from Abbott Laboratories in January 2013. The company is based in suburban Chicago. The shares are a component of the S&P 500.
RatingPrice Target